MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, March 30, 2009

Fampridine-SR (4-aminopyridine) is a new drug in development to help improve walking ability in people with multiple sclerosis

Fampridine-SR ("4-aminopyridine", "4-AP", “fampridine”) is an investigational oral, sustained-release tablet formulation of 4-aminopyridine. In laboratory studies fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged.

Clinical History of Fampridine-SR in Multiple Sclerosis (MS)

Acorda recently completed a Phase 3 clinical study of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with all types of MS.

View a video* illustrating Fampridine-SR’s mechanism of action:

Large (4.0MB)
Small (2.8MB)

Researchers have shown that, contrary to popular belief, most people with spinal cord injury (SCI) do not have severed cords; rather, most have blunt damage to the cord. The great majority of such individuals have some axons within the spinal cord that survive the injury. However, these surviving axons often are damaged and lose part of their myelin, the insulating sheath that permits electrical impulses to be conducted down the axon. Nerve impulses "short circuit" in demyelinated axons, much like electricity in a wire whose insulation is stripped. Thus, even though a demyelinated axon is alive, it cannot transmit motor or sensory impulses. In multiple sclerosis (MS), the myelin is believed to be damaged by the body's own immune system, rather than by physical trauma as in SCI.

Fampridine-SR's major action is to block specialized potassium channels on axons. When an axon is demyelinated after injury, large numbers of these potassium channels are exposed and "leak" potassium ions, causing the axon to "short circuit".

By closing the exposed potassium channels, Fampridine-SR permits the axon to transmit impulses again, even in a demyelinated state.

*Video requires Quicktime to view. Download Quicktime now.

Tell us what you think of this hopeful new medication. Thank You

1 comment:

Anonymous said...

I have been following this drug for about 2 years now and hope it will help. I have been helped somewhat with Tysabri but hope this drug will help w/ walking longer and further. I miss really taking a walk and it is my hope Fampridine will fulfill this dream. I can survive most of these lousy symptoms, but I really miss the feeling and joy of walking ..anywhere I want. Let's keep our fingers and toes crossed!!